ranolazine tablet film coated extended release

1 INDICATIONS AND USAGE Ranolazine extended-release tablets are indicated for the treatment of chronic angina. Ranolazine extended-release tablets may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. Ranolazine extended-release tablets are an antianginal indicated for the treatment of chronic angina. ( 1 )

actavis pharma, inc.

FDA Reported Adverse Reactions
`[1] off label use` `[2] diarrhoea` `[3] fatigue` `[4] nausea` `[5] drug ineffective` `[6] death` `[7] pneumonia` `[8] pyrexia` `[9] dyspnoea` `[10] plasma cell myeloma`

5 years ago

OVAL PINK Logo 419

5 years ago

Logo 419 OVAL PINK

16 HOW SUPPLIED/STORAGE AND HANDLING

RANOLAZINE extended-release tablets are supplied as follows: 500 mg - Each gray, oval shaped, film-coated tablet debossed with and 418 on one side and plain on the other side contains 500 mg of

RANOLAZINE. Tablets are supplied in bottles of 60 tablets (NDC 45963-418-06). 1,000 mg - Each pink, oval shaped, film-coated tablet debossed with and 419 on one side and plain on the other side contains 1,000 mg of

RANOLAZINE. Tablets are supplied in bottles of 60 tablets (NDC 45963-419-06). Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP. 1 1

More pills like OVAL Logo 419

Related Pills

12 HR ranolazine 500 MG Extended Release Oral Tablet

actavis pharma, inc.

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site